<DOC>
	<DOCNO>NCT01224028</DOCNO>
	<brief_summary>This study evaluate efficacy safety tacrolimus patient non-nephrotic albuminuric , normotensive IgA nephropathy 16 week treatment tacrolimus ( Prograf ) placebo .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Tacrolimus Korean Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patients IgA nephropathy confirm renal biopsy Serum creatinine measurement ≤1.5mg/ml MDRD estimate GFR ≥ 45ml/min/1.73m2 ( MDRD : Modification Diet Renal Disorder ) UACR level 0.3 3.0 Blood pressure measurement &lt; 130/80mmHg Use immunosuppressant two week within last one month Concomitant use ACE inhibitor , ARB , steroid immunosuppressant , NDHPCCB , diuretic , omega3 fatty acid analogue &amp; additional dietary treat igA nephropathy ( ACE : Angiotensin Converting Enzyme , ARB : Angiotensin Receptor Blocker , NDHPCCB : Nondihydropyridinetype Calcium Channel Blocker Pregnant breastfeeding patient . Patients plan bear child breastfeed study within 6 month completion study Hypersensitivity investigational drug macrolide agent Use potassiumsparing diuretic Persistence liver function abnormality 1 month presence acute active hepatitis Other investigational drug within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Calcinurin inhibitor</keyword>
	<keyword>Albuminurea</keyword>
	<keyword>Proteinurea</keyword>
	<keyword>FK506</keyword>
</DOC>